

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣 藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON TUESDAY, 23 DECEMBER 2025

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING

Reference is made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of the extraordinary general meeting (the “**EGM**”) of Consun Pharmaceutical Group Limited (the “**Company**”) both dated 2 December 2025. Unless otherwise indicated, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The Board of Directors is pleased to announce that all the proposed resolutions set out in the Notice were duly passed by way of poll at the EGM held on Tuesday, 23 December 2025. All Directors attended the EGM in person or by video conference.

As at the date of the EGM, the total number of issued Shares was 848,408,407 Shares, and the total number of Shares entitling the holders to attend and vote for or against the resolutions at the EGM was also 848,408,407 Shares. No Shareholder entitled to attend the EGM was required to abstain from voting in favour of the resolutions at the EGM as set out in Rule 13.40 of the Listing Rules. None of the Shareholders was required under the Listing Rules to abstain from voting on the resolutions at the EGM. None of the Shareholders had stated their intention in the Circular to vote against or to abstain from voting on the resolutions at the EGM.

The poll results in respect of each of the resolutions are as follows:

Ordinary resolutions*		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To approve and adopt the Share Award Scheme of the Company.	420,696,443 (74.65%)	142,867,214 (25.35%)
2.	To approve and adopt the sublimit for Service Providers (as defined in the Share Award Scheme of the Company).	420,707,443 (74.65%)	142,856,214 (25.35%)

Special resolution*	Number of votes cast and approximate percentage of total number of votes cast	
	For	Against
3. To approve the proposed amendments to the existing Memorandum and Articles of Association of the Company, and the adoption of the third amended and restated Memorandum and Articles of Association of the Company.	563,563,657 (100%)	0 (0%)

* The full text of the resolutions is set out in the Notice.

As more than 50% of the votes were cast in favour of each of the ordinary resolutions (resolutions nos. 1 to 2), such resolutions were duly passed by the Shareholders as ordinary resolutions by way of poll.

As more than 75% of the votes were cast in favour of the special resolution (resolution no. 3), such resolution was duly passed by the Shareholders as a special resolution by way of poll.

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the EGM.

By Order of the Board
Consun Pharmaceutical Group Limited
Chairman
AN Meng

Hong Kong, 23 December 2025

As at the date of this announcement, the Board comprises Mr. An Meng and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua and Professor Zhu Quan as non-executive Directors; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.